Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can we print .12c again? Cash ready!!! OMTK$$
Like for real!!!....for real??
Really!! :;)
How to Tell If Your Biotech Micro Cap Has Big Potential
There are two main guardian indicators to look for when assessing the risk for a micro cap: management and platform/development model.
Management: Many a biotech firm starts as the brainchild of some scientific researcher, working anonymously and unheralded in an obscure university lab, who has come across an interesting discovery that suggests a new approach to treating some particular disease.
And so the researcher finds seed money from private investors or a grant-making foundation, gets a company logo, appoints him or herself as CEO, and goes to work. Eventually, it may come time to make an IPO (initial public offering) and bring investors on board.
At first, with every quarterly report, the news seems to get better. But sooner or later, the company repeatedly fails to meet its guidance, and the stock shares lose much, if not all, of their value.
What happened?
Wrong pilot at the helm. Scientists do science well. Business people do business well. Crossovers do happen – but not dependably or often.
Which leads us to this rule: Be very, very suspicious of company management headed by a scientist who has no business experience. These folks believe passionately in what they're doing, and they'll get you to believe passionately right along with them. But going from scientific passion to financial success should ultimately fall to the hands of someone with experience making that journey.
A company's chief science officer, of course, should be just that: a scientist. But in a CEO, look for years of experience in company and capital formation, market development, mergers and acquisitions, licensing, and corporate governance.
That won't guarantee your success, but it will go a long way in protecting against failure.
A solid development plan: For you to assess how your equity is doing at any given point, you need to have touchstones against which you can measure success or failure, and this is as true for micro caps as it is for pharmaceutical giants.
This means the firm you're investing in needs to have a solid business model (a plan for getting to profitability), a strong platform (a credible scientific basis for its pipeline development program), and mile markers, such as binary regulatory catalysts (clinical trial data releases and company guidance goals) that will help push share value upward.
Very often, you can find this kind of information in corporate presentations and quarterly earnings call transcripts, which you'll generally find on a company's website.
Look for well-defined goals, not pie-in-the-sky daydreams. There's a lot of space between "…We hope to cure lung disease someday," and "…We're initiating a phase 2 study for our medication in the treatment of bacterial pneumonia, starting next quarter."
Look for numbers: "We expect to earn $3 million in revenue per quarter in the coming year, a 3% gain over last year's numbers for the same time period," and not, "The company hopes to continue its positive progress in the coming months."
Look for dates: "We expect to announce topline date from our phase 2 trial by the end of Q3 2019," and not, "We continue to collect proof of our product's value and hope to have it ready for marketing next year."
Oh, and be sure the company is reporting regularly and promptly to the SEC, as required by law. If it doesn't, it will be delisted from exchanges like the Nasdaq.
The Trend Is the Ultimate Test
Once you're past these first steps, the one thing you need to consider before all others is this: Is this company's pipeline taking advantage of a fad or a trend?
Because it absolutely should be.
What is the health reporter on your local TV station talking mostly about? What kinds of medical stories are showing up on satellite radio or your go-to website? What sorts of health stories are you hearing from your friends and family?
"I hear they've found a cure for diabetes."
"There's this fabulous new diet pill that's supposed to work overnight."
"Did you hear all these Hollywood stars are having their double chins reduced?"
"It says on the news that West Nile Virus is spreading everywhere, but they're coming up with new vaccines every day."
If it's in the media, it's giving audiences a taste of hope, and that hope builds interest until it becomes a trend.
Any young company lucky enough to be riding that trend, even if it doesn't yet have an extensive clinical paper trail, can whet investors' interest and make strong profits in a short period of time.
$$$$AMBS
no one on this board is CRIPPLED....EXCEPT??
this is pennyland....what else?
ajmho
GM.... ??? you did'nt really sell ? Did you?:( $$
er Wolf Wolf.....Nice :)!!!
"Leggo".....or Let it GO.....Let it ripp...make "SECRET TELL IT ALL".
MAKE SECRET TELL ON IT'S OWN DAMMN SELF[color=red][/color]
$$$660,000.00 dollars $
Thank You !!!....
$AMBS got their IP back....
Cleaned up the books
$ambs has secured financing....
NOW WHAT???
MEMORY LANE :) JP LOOKING FOR A $$JOB$$
PER JP: JPetroInc
Monday, March 11, 2013 8:40:23 PM
you are an Angel - not yet but still keeping the faith and praying hard - will let you know when I do. Thanks for the kind thoughts and genuine sentiment - it means alot....
All the Best, JP
PER JP he has remained consistant with passion for $AMBS
JPetroInc Friday, 12/30/16 01:28:44 PM
Re: Chelby84 post# 125705 0
Post # of 128427
AMBS needs to get their IP back and the company out of default with Magna before anyone will even remotely look at it again -
Why? Because as 100% Owner of AMBS, Magna is serial diluting, and will continue to do so until something changes. There is $0.00 revenue here - so dilution will remain rampant daily.
Next, you have an inexperienced & novice CEO who is not well grounded in reality, coupled with a management team that has lost the trust of the investment community at large, and has earned itself the reputation as being totally inept and incompetent.
The best thing that could happen here is if a 3rd party entity bought out the defaulted paper owed Magna, cleaned house of all the losers, and took formal reigns of the company going forward. They could keep Gerald as a consultant long enough to take flight and then eject him from ever having anything to do with AMBS ever again.
And the above would be just a start of things needed to begin turning things around.
AJMHO JP
Let's Let her RUN... RUN JANE ..RUN!!!
Thanks GreaseMShoes!!
I've waited patiently for last 5 years!!!
It's time $$ OMTK $$ :)
I'm not a BASHER of $AMBS....I'm a cheeleader! I was replying to a basher's post... please read!
$AMBS has not started trading? I want more!!
Waiting , Playing, flipping!
I will just WAIT!......THIS TIME AROUND$$$
No longer playing, and flipping....$$INVESTING
YES!... everyone can see it if you are awake$$
YES! ATTBF is listed on the index.... Canadian $.84 cents
MCIG...it HAULING AZZ
I still believe In Amarantus Bioscience! and I will buy and hold as long as it takes.....it will not be a if I would've, could've moment for me one day.
Chelby84
1 Billion O/S shares !!!! wowza!!
When is the party?
The r/verse split party??
Still holding
Still waiting
WINNER!!!
hell.,
this clown CEO charged the investors and reorganization fee???
my account was charged $20. fee for this junk!!!!!
Lolz!!!! Real funny!!!
I guess we'll laugh together in sync real soon?
I don't understand trading 101.....
AMARANTUS BIOSCIENCES HOLDINGS INC - Sale price rose to 0.3800
Last Sale: 76.66 at 09:36:21 EST
Current Quote for AMBS
Last: 76.66 DJI 17634.74 (0)
Change: 76.582 (+98182.05 %) NASDAQ: 4688.53 (0)
High: 76.66 S&P500 2039.82 (0)
Low: 0.0752
Annual High: 76.66
Annual Low: 0.0391
Previous Close: 0.078
Volume: 59768
100-Day Avg. Volume: 7260688
200-Day Moving Avg: 0.10
When did AMBS high reach $ 76.66?
MERRY CHRISTMAS 'RISKreturn168'; and a MERRY CHRISTMAS TO ALL :)
AMBS
Chelby84
Cudos...CONNECT THE DOTS'.. this is worth a wink, a smile, and a smirk.lol :)
GOOD LUCK ALL,
Stock News Overview : Article
Rapid Delivery Program Product Portfolio Expands to Biopharmaceutical Injectable Market
11 minutes ago - DJNF
BD AccelerateSM Program Designed to Bring Pharmaceutical Customers' Drugs to Market Faster
FRANKLIN LAKES, N.J., Nov. 19, 2013 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that the BD Accelerate(SM) program now offers a solution for the biopharmaceutical injectable drug market with the BD Neopak(TM) Glass Prefillable Syringe system. This make-to-stock program is designed to facilitate expedited delivery, within two weeks, of fully-validated BD syringe systems and associated quality systems documentation to pharmaceutical customers.
Launched in 2011, the program was designed to offer pharmaceutical customers faster access to fully-validated syringe systems that are optimized for biologics, vaccines and other parenteral medicines. Based on BD's high-speed manufacturing capabilities, the BD Accelerate(SM) program allows the company to produce and store large quantities of fully-validated syringe components. This program represents a significant reduction in lead time versus traditional processes and provides customers with the advantage to initiate testing earlier in the drug development process.
"By offering faster access to a syringe system that is specifically engineered for the delivery of biopharmaceutical drugs, BD is positioned to provide an important advantage to companies developing these products to address a wide range of unmet healthcare needs," said Eric Borin, Vice President and General Manager -- Americas, BD Medical -- Pharmaceutical Systems. "The availability of the BD Neopak(TM) Glass Prefillable Syringe system through the BD Accelerate(SM) program demonstrates BD's understanding of its pharmaceutical partners' current challenges when bringing drugs to market for patients."
Building on more than 100 years of industry expertise, BD selected products suited to specific market needs with attributes to reduce regulatory and drug compatibility risks intended to enable pharmaceutical companies to expedite drug products through the development stages. The current syringe systems offered through the program include BD Neopak(TM) Glass Prefillable Syringes, BD Hypak(TM) Glass Prefillable Syringes and BD Hypak(TM) Glass Prefillable Syringes for Biotech. As of January 2013, more than 40 BD pharmaceutical partners have participated in the BD Accelerate(SM) program.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
Contact:
Jamie Yacco
funny,,,he heheeehee; i'm having lunch with his daddy next week!!! :)
WHEN THE PPS GET TO $10.... CALL ME AND WAKE EVERYONE UP @ 954CHELBY84
AMBS
It's all good!! Though your statement is sound and have alerted me... As I recall the exact statement elsewhere. AMBS
I spoke to Gerald this morning, he says,"he is looking forward to the afterparty, drinks and small talks"
lordhavemercy,
AMBS
FOR THE PPL THAT SAY THEY KNOW.. KNOW NOTHING...FOR THE PPL THAT KNOW...SAY NOTHING!!!
I totally agree with you!!!
quote:
p.s. If you can get me a better price I'd appreciate it. I'm a few shares short of owning 1% of the company.
50k shares@ .06 cents to get me over 200k shares would work too!!! I'm not greedy.
Chelby84
Thanks kindly for your response. Your posts are greatly appreciated and informative.
Chelbly 84
heads up Retiredtech!!
RETIREDtech?, which way are you headed "south"? come what may, I got powder...leggo!
ambs
That is correct. Wanting to purchase 28million shares @ a minimum of $2.36 price per share...I know those persons too!
ambs
I also know the person whom would love to sell to them @ $2.36 pps...lol
Laughter is good for the soul!! LMAO.....most days you could keep a lid on some of this funny ozz stuff. lol. :)
But you are correct in your statement...12 people..the same 12 people! out of well over 600 people that may follow the discussions!
The mods should at least rotate the 12 people with another set of of 12 people! ...give the original 12 people comp time and a leave of absence..
appreciation for the science as of late...
Chelby84.... GLTA
Yes; go ahead listen first. Secondly do what the chart tells you to do!! Buy. Buy, and Buy a lot more. Ambs
$10. Dollars pps..... I am guessing someone is in the "know"...heck just maybe YOU!!!!!
Ambs....
NEWS OUT!! REVERSE SPLIT EFFECTIVE August 12, 2013
News for 'UNGS' - (US Natural Gas Corp Announces Reverse Stock Split and Effective Date)
Aug 09, 2013 (ACCESSWIRE via COMTEX) -- US Natural Gas Corp Announces Reverse
Stock Split and Effective Date
Effective Date of August 12, 2013
ST. PETERSBURG, Fla. August 9, 2013 -- US Natural Gas Corp (OTC Pink:UNGS), an
energy exploration company with operations in the Appalachian Basin announced
today that its Board of Directors has approved the implementation of a 1-for-300
reverse stock split of its common stock, following approval by a majority vote
of shareholders holding the Company's capital stock . The reverse stock split
will be legally effective on August 12, 2013 (the "Effective Date"). The
split-adjusted shares of the Company's common stock will begin trading on August
12, 2013 under the symbol "UNGSD" for 20 days. A new CUSIP number has been
assigned to the Company's common stock as a result of the reverse stock split.
As a result of the reverse stock split, immediately upon the Effective Date each
three hundred shares of the Company's outstanding common stock will
automatically be combined into one share, without any change to the par value
per share. The Company currently has 8,503,396,768 common shares outstanding.
Upon completion of the reverse stock split, the Company will have 28,344,656
common shares outstanding with 2 Billion common shares authorized. No fractional
shares will be issued in connection with the split and stockholders who would be
entitled to fractional shares will receive a whole share of common stock in lieu
of receiving fractional shares.
Olde Monmouth Stock Transfer, the Company's transfer agent, will update the
Company's records to reflect the change. Olde Monmouth Stock Transfer will
provide instructions to stockholders relating to the issuance of book-entry
evidence of ownership giving effect to the reverse split and name change and to
the issuance of new stock certificates
About US Natural Gas Corp
US Natural Gas Corp is an independent energy company principally engaged in the
acquisition, exploration and development of mature long-lived oil and natural
gas properties. The company's current operations are concentrated in the
Appalachian Basin within the states of Kentucky and West Virginia with core
assets consisting of 17,000 acres of mineral rights leases and interest in
approximately 150 oil and gas wells. More information on US Natural Gas Corp can
be found on the Company's website at www.usnatgascorp.com.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. When
used in this press release, the words "anticipate," "believe," "estimate,"
"may," "intend," "expect" and similar expressions identify such forward-looking
statements. Actual results, performance or achievements could differ materially
from those contemplated, expressed or implied by the forward-looking statements
contained herein, and while expected, there is no guarantee that we will attain
the aforementioned anticipated developmental milestones. These forward-looking
statements are based largely on the expectations of the Company and are subject
to a number of risks and uncertainties. These include, but are not limited to,
risks and uncertainties associated with: the impact of economic, competitive and
other factors affecting the Company and its operations, markets, product, and
distributor performance, the impact on the national and local economies
resulting from terrorist actions, and U.S. actions subsequently; and other
factors detailed in reports filed by the Company. Additional risks and
uncertainties are set forth in the Company's Unaudited Annual Report for the
year ended December 31, 2012, which can be found on the OTC Markets website,
www.otcmarkets.com.
Contact:
US Natural Gas Corp
(727) 482-1505